506391 TumorGenesis® Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince OCMI-Le) (Liquid)

$579.00

Primary Endometrioid and Mucinous Ovarian Cancer Media (Ince)

Suggested Usage

PRIMARY HUMAN OVARIAN CARICINOMA CELL LINES Endrometrioid Primary Endrometrioid Primary Mucinous Primary

Tan A. Ince, MD, PhD – Fighting Cancer by Keeping Cancer Cells Alive … https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive/

Feb 12, 2017 – Professor Ince was a visiting clinical scientist at the Massachusetts Institute of Technology from 2000 to 2007, where he developed a new cell culture nutrient medium that is now widely used to grow human breast and ovary cells.

Clear
SKU: 506391 Category:

Appearance
Red to orange, clear, complete

Colorless)
FOMI Bullet 1 Included (506391B, Supplied as a liquid. Vortex, spin down and add whole vial to 506391.

Storage (506391B)
Liquid is stable at 4°C.

Pink)
FOMI Bullet 2 Included (506391C, Supplied as a liquid. Thaw, vortex, spin down and add whole vial to 506391.

Storage (506391C)

Liquid is stable at -20°C.

(w/o supplements)
Storage and Stability (506391) Store at 4°C. Do not freeze. Light sensitive, store in the dark. Stable for 6 months w/o supplements.

(w/ supplements)
Storage and Stability (506391) Complete media with supplements is stable for 6 weeks at 4°C. Do Not Freeze. Light sensitive, store in the dark.

Country of Origin
United States

Customer supplied
To be supplemented with 5% fetal bovine serum to media To be supplemented with Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Important Note 
Cholera toxin is NOT included in the liquid media nor the bullet. Shipping regulations have made it increasingly difficult to ship. Please procure from your local supplier. Calbiochem 227036 Cholera Toxin w/o azide, 25ng/ml to media.

Licensed by TumorGenesisTM. Manufactured for research use by US Biological

1. Tan A. Ince, MD, PhD - Fighting Cancer by Keeping Cancer Cells Alive ...https://www.scientia.global/tan-ince-md-phd-fighting-cancer-keeping-cancer-cells-alive.|2. AE Witt, CW Lee, TI Lee, DI Azzam, B Wang, C Caslini, F Petrocca, J Grosso, M Jones, EB Cohick, AB Gropper, C Wahlestedt, AL Richardson, R Shiekhattar, RA Young and TA Ince, Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer, Oncogene, 2016. DOI: 10.1038/ onc.2016.337. 3. A Thakkar, B Wang, M Picon-Ruiz, P Buchwald and TA Ince, Vitamin D and androgen receptor-targeted therapy for triple-negative breast cancer, Breast Cancer Res. Treat., 2016, 157, 77–90. 4. TA Ince, AD Sousa, MA Jones, JC Harrell, ES Agoston, M Krohn, LM Selfors, W Liu, K Chen, M Yong, P Buchwald, B Wang, KS Hale, E Cohick, P Sergent, A Witt, Z Kozhekbaeva, S Gao, AT Agoston, MA Merritt, R Foster, BR Rueda, CP Crum, JS Brugge, GB Mills, Characterization of twenty-five ovarian tumour cell lines that phenocopy primary tumours, Nat. Commun., 2015, 6, 7419. 5. S Santagata, A Thakkar, A Ergonul, B Wang, T Woo, R Hu, JC Harrell, G McNamara, M Schwede, AC Culhane, D Kindelberger, S Rodig, A Richardson, SJ Schnitt, RM Tamimi and TA Ince, Taxonomy of breast cancer based on normal cell phenotype predicts outcome, J. Clin. Invest., 2014, 124, 859–870.